Tiziana Advances Alzheimer’s Treatment with FDA Nod
Company Announcements

Tiziana Advances Alzheimer’s Treatment with FDA Nod

Tiziana Life Sciences (TLSA) has released an update.

Tiziana Life Sciences has received FDA approval to begin administering intranasal foralumab to a patient with moderate Alzheimer’s disease under an Expanded Access IND, with treatment starting as early as July. The company believes that foralumab, as the only fully human anti-CD3 monoclonal antibody, may slow cognitive decline by targeting neuroinflammation, a key factor in Alzheimer’s pathology. This follows previous IND clearances, positioning foralumab as a potentially groundbreaking treatment for various stages of Alzheimer’s disease.

For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Highlights Advancements at BIO-Europe 2024
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Announces $10 Million Share Offering
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Reports Promising Obesity Therapy Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App